Compare RDY & XPEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDY | XPEV |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | India | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 9.2B |
| IPO Year | 2001 | 2020 |
| Metric | RDY | XPEV |
|---|---|---|
| Price | $14.19 | $9.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 25 |
| Target Price | $14.26 | ★ $18.00 |
| AVG Volume (30 Days) | 2.9M | ★ 5.6M |
| Earning Date | 10-23-2026 | 11-16-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.59 | $12.70 |
| Revenue Next Year | $12.06 | $26.03 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.36 | $8.99 |
| 52 Week High | $15.67 | $28.20 |
| Indicator | RDY | XPEV |
|---|---|---|
| Relative Strength Index (RSI) | 77.10 | 39.11 |
| Support Level | $13.99 | N/A |
| Resistance Level | $14.20 | $10.06 |
| Average True Range (ATR) | 0.23 | 0.28 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 89.58 | 6.67 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Founded in 2015, XPeng is a leading Chinese electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold about 430,000 EVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.